| Literature DB >> 33716115 |
Stefano Negrini1, Jody-Anne Mills2, Chiara Arienti3, Carlotte Kiekens4, Alarcos Cieza5.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic resulted in a surge of research activity. Since its outset, efforts have been made to guide the rapid generation of research in medicine. There are gaps in some areas of rehabilitation research for patients with COVID-19. The development of a specific research framework might serve to help monitor the status of research (mapping), shape and strengthen research by pointing to under-investigated areas, and promote rehabilitation research in this context. This article introduces and discusses the COVID-19 Rehabilitation Research Framework (CRRF) and presents the methodology used for its development. The questions have been developed among the World Health Organization (WHO) Rehabilitation Programme, Cochrane Rehabilitation, and the experts of its Rehabilitation-COVID-19 Evidence-based Response Action International Multiprofessional Steering Committee. The framework is divided into 2 parts and includes 20 questions organized in 4 groups: epidemiology, and evidence at the micro- (individual), meso- (health services), and macro- (health systems) levels. The CRRF offers a comprehensive view of the research areas relevant to COVID-19 and rehabilitation that are necessary to inform best practice and ensure rehabilitation services and health systems can best serve the population with COVID-19. The collaboration between Cochrane Rehabilitation and the WHO Rehabilitation Programme in establishing the CRRF brought together perspectives from the health systems, health management, and clinical evidence. The authors encourage researchers to use the CRRF when planning studies on rehabilitation in the context of COVID-19.Entities:
Keywords: COVID-19; International Classification of Functioning, Disability and Health; Rehabilitation
Mesh:
Year: 2021 PMID: 33716115 PMCID: PMC7948530 DOI: 10.1016/j.apmr.2021.02.018
Source DB: PubMed Journal: Arch Phys Med Rehabil ISSN: 0003-9993 Impact factor: 3.966
International Multiprofessional Steering Committee of the REH-COVER Action of Cochrane Rehabilitation
| Member | Area of Expertise | Organization | Country |
|---|---|---|---|
| Carlotte Kiekens | Physical and rehabilitation medicine | Codirector | Belgium |
| Chiara Arienti | Osteopathy and methodology | Coordinator | Italy |
| Maria Gabriella Ceravolo | Physical and rehabilitation medicine | Member | Italy |
| Pierre Côté | Chiropraxis and methodology | Member | Canada |
| Anne Cusick | Occupational therapy | Member | Australia |
| Francesca Gimigliano | Physical and rehabilitation medicine | Cochrane Rehabilitation | Italy |
| Allen Heinemann | Psychology | Member | United States |
| Jody-Anne Mills | Occupational therapy | Representative | Australia |
| Farooq Rathore | Physical and rehabilitation medicine | Representative | Pakistan |
| Marco Rizzi | Infectious diseases | Member | Italy |
| Geert Verheyden | Physical therapy | Member | Belgium |
| Margaret Walshe | Speech and language therapy | Member | Ireland |
| Stefano Negrini | Physical and rehabilitation medicine | Director | Italy |
First part of the COVID-19 rehabilitation research framework (CRRF): scope of rehabilitation research enquiry
| COVID-19 Rehabilitation Research Framework Part I. Scope of Rehabilitation Research Enquiry | |
|---|---|
| LFRI | Activity limitation(s) |
| Impairment(s) | |
| Participation restriction(s) | |
| COVID-19 phases of care | Acute: LFRI during COVID-19 infection |
| Postacute: LFRI continuing from the acute phase of COVID-19 and its treatment | |
| Permanent: LFRI unresolved or not solvable, and causing a new health condition | |
| Late onset: LFRI appeared as a consequence of COVID-19 but after the end of the acute phase | |
| Populations | People with a preexisting health condition |
| People with disability and/or experiencing disability at the time of infection | |
| Country economic context | High-income countries |
| Low- and middle-income countries | |
Second part of the COVID-19 rehabilitation research framework (CRRF): areas of rehabilitation research enquiry and associated questions
| COVID-19 Rehabilitation Research Framework Part II. Areas of Rehabilitation Research Enquiry and Associated Questions | |
|---|---|
| 1. Epidemiology of LFRI due to COVID-19 | |
| 1.1 | What are the LFRI? |
| 1.2 | Which is the clinical presentation (sign, symptoms, diagnostic examination) of the LFRI? |
| 1.3 | What is the prevalence of the LFRI? |
| 1.4 | What is the natural history of the LFRI? |
| 1.5 | What are the determining factors of the LFRI and how do they influence possible changes of the LFRI? Including the following: |
| 1.5.1 | Demographics |
| 1.5.2 | Health |
| 1.5.3 | Etiology |
| 1.5.4 | Acute treatment |
| 2. Evidence on rehabilitation for lfri due to COVID-19 at the individual level (microlevel) | |
| 2.1 | What is the evidence on the type of outcomes for LFRI? (ie, outcomes to be considered when treating LFRI) |
| 2.2 | What is the evidence on the effect of interventions for LFRI? |
| 2.3 | What is the evidence on adverse effects/harms/disadvantages of interventions for LFRI? |
| 2.4 | What is the evidence on the cost-effectiveness of interventions for LFRI? |
| 3. Evidence on rehabilitation for lfri due to COVID-19 at the service level (meso-level) | |
| 3.1 | What is the evidence on accessibility (availability, access, utilization) to services for LFRI due to COVID-19? |
| 3.2 | What is the evidence on workforce and/or technology requirements for addressing LFRI due to COVID-19? |
| 3.3 | What is the evidence on changes to the provision of rehabilitation services as a consequence of the pandemic? |
| 4. Evidence on rehabilitation for lfri due to covid-19 at the system level (macro-level) | |
| 4.1 | What is the evidence on the need for services for LFRI due to COVID-19? |
| 4.2 | What is the evidence on the financing of services for LFRI due to COVID-19? |
| 4.3 | What is the evidence on health systems requirements for LFRI due to COVID-19? |
| 4.4 | What is the evidence on the regulation of delivery of services for LFRI due to COVID-19? |
| 4.5 | What is the evidence on changes in the health systems related to rehabilitation as a consequence of the pandemic? |
Fig 1Growth of evidence on rehabilitation and COVID-19 based on the monthly living systematic review conducted by the Steering Committee,,,30, 31, 32, 33, 34, 35 following the Oxford Centre for Evidence-Based Medicine level of evidence levels of evidence, where level 1 is the strongest and level 4 is the lowest.
Fig 2This figure represents the evidence mapping on rehabilitation and COVID-19 based on the monthly living systematic review conducted by the Steering Committee.,,30, 31, 32, 33, 34, 35 The map gathers in a single view the quantity of information in the literature and its distribution according to the CRRF. All details of the map can be seen on the Cochrane Rehabilitation website at the link https://rehabilitation.cochrane.org/covid-19/reh-cover-interactive-living-evidence. The columns include the LFRI divided in the different COVID-19 phases of care and populations according to Part I of the CRRF (see table 1), and the rows include the research questions of Part II of the CRRF (see table 2). In each resulting square, 4 circles represent the quality of evidence (1 per color: RCT, non-RCT, analytical, descriptive studies) and the number of studies (the bigger the circle, the more studies). Clicking on the circles, it is possible to “explode” the information and retrieve all single articles with related information.
Summary of the distribution of current COVID-19 evidence,,30, 31, 32, 33, 34, 35 across the framework area of enquiry and associated questions and levels of evidence quality following the oxford centre for evidence-based medicine levels of evidence, where level 1 is the strongest and level 4 is the lowest. microlevel: individuals; meso-level: health services; macro-level: health systems.
| No. of Publications Per Evidence Quality Level | |||||
|---|---|---|---|---|---|
| Question by Framework Area of Enquiry | 1 | 2 | 3 | 4 | Total, n (%) |
| Epidemiology | |||||
| 1.1 Clinical presentation | 0 | 0 | 3 | 50 | 53(31) |
| 1.2 Prevalence | 0 | 0 | 13 | 6 | 19(11) |
| 1.3 Natural history1.4 determining and modifying factors | 0 | 0 | 15 | 58 | 73(43) |
| Micro-level | |||||
| 2.2 Interventions (efficacy)2.3 interventions (harms) | 0 | 1 | 4 | 4 | 9(5) |
| Meso-level | 0 | 0 | 5 | 10 | 15(9) |
| Macro-level | 0 | 0 | 0 | 0 | 0 |
| Total, n (%) | 0 | 1(1) | 40(24) | 128(76) | 169(100) |
Because of the paucity of articles on many questions, the authors resumed the questions according to the reported categories. There are currently no publications addressing the questions not included.